Kimberly Stegmaier, MD
Co-Director of the Pediatric Hematologic Malignancy Program
Ted Williams Chair
Associate Professor of Pediatrics, Harvard Medical School
Chemical screening, Neuroblastoma, Ewing Sarcoma, Hematologic malignancies, Cancer genomics
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Pediatric Hematology/Oncology, 2002
Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
Harvard Medical School, 1996
Kimberly Stegmaier, M.D., is an Associate Professor of Pediatrics at Harvard Medical School, a Principal Investigator in Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), and anAttending Physician at the Boston Children’s Hospital Boston (BCH) and DFCI. She is the Co-director of the Pediatric Hematologic Malignancies Program at DFCI and BCH and is also an Associate Member of the Broad Institute of Harvard and MIT. She received her B.S. from Duke University and her M.D. from Harvard Medical School. She completed her residency at BCH and a post-doctoral pediatric hematology-oncology fellowship at DFCI/BCH. In 2006, she launched her own laboratory effort at DFCI.
Dr. Stegmaier’s laboratory integrates chemical biology, genomic, and proteomic approaches to discover new lead compounds and protein targets for cancer therapy. She has focused her efforts on the acute leukemias and two pediatric solid tumors of childhood: Ewing sarcoma and neuroblastoma.